Health and Healthcare
Cell Therapeutics, Ready To Tap Financing (CTIC)
Published:
Cell Therapeutics (NASDAQ: CTIC) has filed an open mixed securities shelf registration for up to $150 million. This will allow it to sell debt securities, common stock, preferred stock, and warrants.
Last Tuesday, the company announced progress in beginning Phase III testing for its non-Hodgkin’s lymphoma treatment. Friday, the company filed its annual report.
Shares have showed no reaction to the filing, with a 0% change, sitting at $0.66. The 52-week range is $0.47 to $7.56 and its current market cap is only $62.5 million.
Rachel Lopez
March 31, 2008
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
